The Powerhouse for Anti-infectives

2021-09-20

AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections

Start of a pilot study with immunomodulator AIC649 for treatment of asymptomatic or mildly symptomatic COVID-19-patients to prevent more severe symptoms including respiratory failure that may develop with progression of the disease.

Read more

2021-09-17

AiCuris befürwortet und unterstützt die Nationale Allianz für Pandemie-Therapeutika (NA-PATH)

NA-PATH ist eine Initiative des Helmholtz-Zentrums für Infektionsforschung (HZI) und des Deutschen Zentrums für Infektionsforschung (DZIF), die einen Sektor-übergreifenden Ansatz vorschlägt, um auf zukünftige Pandemien durch virale Erreger vorbereitet zu sein.

Read more

2021-07-08

AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of herpes simplex virus infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial

Start of pivotal phase 3 development with its proprietary lead compound pritelivir, a novel helicase-primase inhibitor, following encouraging phase 2 interim results achieved in the phase 2 part of its clinical phase 2/3 trial, PRIOH-1.

Read more

2021-05-25

AiCuris AG Announces Dr. Stefan Oschmann, Former Merck CEO, to Chair the AiCuris Supervisory Board

The Supervisory Board appointed Dr. Stefan Oschmann as Chairman. He succeeds Helmut Jeggle, Chief Executive Officer of Salvia GmbH, who stepped down as planned from his role as Interim-Chairman of the initial Supervisory Board of AiCuris AG

Read more

2021-03-30

AiCuris expands its Management with Prof. Dr. Hubert Trübel joining as Chief Medical Officer and the Appointment of Dr. Tamara Pfaff, Head of Preclinical Development, to the Management Team

Prof. Hubert Trübel joined AiCuris as Head of Clinical Development and Chief Medical Officer. In addition, the Head of Preclinical Development, Dr. Tamara Pfaff, was also appointed to the management team effective April 1, 2021

Read more

2021-02-01

AiCuris changes its legal form: AiCuris Anti-infective Cures GmbH becomes AiCuris AG

Transition will support the Company in exploring additional opportunities for future growth

Read more

2021-01-13

AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative

AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative

Read more

2020-12-02

AiCuris receives approval from BfArM to initiate Compassionate Use Program for Pritelivir in Germany

Approval from the German “Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)” to initiate a Compassionate Use Program (Härtefallprogramm) for pritelivir.

Read more

2020-08-17

AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference

AiCuris has launched a four-pillar program, “PREP – Pandemic and Resistance Emergency Preparedness”

Read more

2020-12-02

Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente

„Wir können lebenswichtige Medikamente zur Behandlung von COVID-19-Patienten zur Verfügung stellen, aber wir benötigen signifikante Unterstützung bei der Finanzierung der Entwicklungs- und Produktionskosten – jetzt!“

Read more